104593A novel treatment for systemic lupus erythematosusClosedCollaborative R&DInnovate UKMedAnnex is developing a new therapeutic called annexuzlimab(tm). It targets and binds to annexin-A1, a protein that occurs naturally in the human body and plays an important role in the response of the immune system to inflammation. There are well known links between inflammation and numerous major diseases including several autoimmune conditions such as rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus. This project is a vital step in the development of annexuzlimab as an innovative therapy with the potential to become a major new drug to extend and improve lives.